XML 50 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)
0 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 27, 2014
Jan. 24, 2013
Feb. 28, 2013
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock split, conversion ratio 0.0833          
Common stock, par value       $ 0.01   $ 0.01
Share-based compensation arrangement by share-based payment award, expiration period       10 years    
Unvested stock options, unrecognized compensation expense weighted average recognition period       3 years    
Stock-based compensation       $ 331,000 $ 164,000  
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options       1,900,000    
Stock options, granted       199,080 25,625  
Stock options, fair value assumptions, risk free interest rate       1.72% 0.78%  
Stock options, fair value assumptions, dividend yield       0.00% 0.00%  
Stock options, fair value assumptions, expected life       4 years 3 months 14 days 4 years 6 months 18 days  
Stock options, fair value assumptions, historical volatility rate       104.71% 105.77%  
Stock options, fair value assumptions, forfeiture rate       1.00% 4.07%  
Common stock rights issued   691,656 149,272 115,432 840,928  
Deferred revenue       1,212,000   1,088,000
Other accrued liabilities       1,809,000   2,037,000
Foreign currency translation adjustment, net of tax       12,000 (173,000) (45,000)
Foreign currency transaction gain (loss), realized       (100,000) 100,000  
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)       5,523,975 2,889,033  
CEO
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock rights issued       83,333    
CFO
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock rights issued       55,000    
Pharmacogenomic services
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Deferred revenue       200,000   200,000
Diagnostic tools
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Deferred revenue       1,000,000   900,000
Additional Paid-in Capital (1) | Selling, General and Administrative Expenses [Member]
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock-based compensation         164,000  
Accumulated Other Comprehensive Income
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Foreign currency translation adjustment, net of tax       $ 12,000 $ (173,000) $ (45,000)
Minimum
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       1 year    
Maximum
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       3 years